EGFR and non-small cell lung carcinoma: Some EMT-associated transcription factors, such as SNAIL, TWIST1, and zing finger E-box binding homeobox 1/2 (ZEB1/2), can be downregulated following LXR activation [14,15], and GW3965 treatment, a synthetic LXR agonist, reverses gefitinib resistance, an inhibitor of the epidermal growth factor receptor (EGFR), in non-small cell lung cancer by inhibiting Vimentin [16].